what is 60 units of semaglutide Dosing Twice Weekly: Science Shows 20 units of semaglutide is

TIRZEPATIDE/ZEPBOUND Once-weekly injection SURMOUNT-1 Trial: Over 20% mean body weight reduction at higher doses Greater likelihood of 15% body weight reduction Newer drug with less overall evidence about effectiveness and side effects Best at improving HbA1C and blood sugar levels More rapid weight loss may also reduce lean muscle mass Possibly reduced nausea and vomiting Higher cost Requires refrigeration Weight gain common after discontinued use From $139/month LEARN MORE - GLP-1/GIP Agonists (Tirzepatide/Zepbound) SEMAGLUTIDE/WEGOVY Once-weekly injection STEP-1 Trial: Up to 15% mean body weight reduction Good long-term evidence about effectiveness and safety Evidence of reduction in diabetic and heart disease risk Slower weight loss may help maintain lean body mass and reduce gallbladder complications Nausea and vomiting similar to other medications Lower cost than Tirzepatide Requires refrigeration Weight gain common after discontinued use From $139/month LEARN MORE - GLP-1 Agonist (Semaglutide/Wegovy) WEGOVY ORAL PILL Daily oral medication Avoids injections OASIS-4 Trial: Up to 16.6% body weight reduction Similar side effect profile to injectable medications Improved blood sugar control in diabetics and pre-diabetics No refrigeration Weight gain common after discontinued use From $124/month How do I get started with a weight loss evaluation

doi: 10.1007/s00253-013-5079-3 68

Important safety information: Retatrutide is an investigational medicine

Side Effects of Semhil Most side effects are mild and improve as the body adjusts

Per FDA labeling, the recommended starting dosage is 2.5 mg once weekly, intended to let the body adjust rather than as a therapeutic weight-management dose

In this trial, MASH resolution without worsening of fibrosis was achieved in 4462% of participants receiving tirzepatide, compared with 10% in the placebo group, and fibrosis improvement of at least one stage without worsening of MASH occurred in up to 55% of tirzepatide-treated individuals versus only 30% with placebo [81]